Hutchmed (China) Limited Vesting of awards under the LTIP
05 März 2024 - 9:30AM
RNS Regulatory News
RNS Number : 5258F
Hutchmed (China) Limited
05 March 2024
Vesting of awards under the Long Term Incentive
Plan
Hong Kong, Shanghai
& Florham Park, NJ - Tuesday, March 5, 2024: HUTCHMED
(China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM;
SEHK:13) announces that following the announcement of the 2023
annual results of HUTCHMED on February 28, 2024, the following
awards granted under the Long Term Incentive Plan ("LTIP") on March
26, 2021 to Dr Weiguo Su and Mr Johnny Cheng were vested on March
4, 2024:-
Award
Holders
|
Number of
American depositary shares ("ADS")
|
Person Discharging Managerial
Responsibilities
|
|
Dr Weiguo Su (Executive
Director, Chief Executive Officer and Chief Scientific Officer)
|
93,545
|
Mr Johnny Cheng (Executive
Director and Chief Financial Officer)
|
15,141
|
Total
|
108,686
|
The notifications set
out below are provided in accordance with
the requirements of the EU Market Abuse Regulation.
(a)
Dr Weiguo Su
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
a)
|
Name
|
Dr Weiguo Su
|
2
|
Reason for the
notification
|
a)
|
Position/status
|
Executive Director, Chief Executive Officer and
Chief Scientific Officer
|
b)
|
Initial notification/Amendment
|
Initial notification
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
a)
|
Name
|
HUTCHMED (China) Limited
|
b)
|
LEI
|
2138006X34YDQ6OBYE79
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
a)
|
Description of the
financial instrument, type of instrument
Identification code
|
ADS each representing
five Ordinary Shares of US$0.10
ADS ISIN:
US44842L1035
|
b)
|
Nature of the transaction
|
Vesting of awards granted on March 26,
2021 under HUTCHMED's LTIP
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
Nil
|
93,545 ADS
|
|
d)
|
Aggregated information
-
|
Aggregated volume
|
-
|
Price
|
|
N/A
|
e)
|
Date of the transaction
|
2024-03-04
|
f)
|
Place of the transaction
|
Outside a trading venue
|
(b) Mr
Johnny Cheng
1
|
Details of the
person discharging managerial responsibilities/person closely
associated
|
a)
|
Name
|
Mr Johnny Cheng
|
2
|
Reason for the
notification
|
a)
|
Position/status
|
Executive Director and Chief Financial
Officer
|
b)
|
Initial notification/Amendment
|
Initial notification
|
3
|
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
|
a)
|
Name
|
HUTCHMED (China) Limited
|
b)
|
LEI
|
2138006X34YDQ6OBYE79
|
4
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
a)
|
Description of the
financial instrument, type of instrument
Identification
code
|
ADS each representing
five Ordinary Shares of US$0.10
ADS ISIN:
US44842L1035
|
b)
|
Nature of the transaction
|
Vesting of awards granted on March 26,
2021 under HUTCHMED's LTIP
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
Nil
|
15,141 ADS
|
|
d)
|
Aggregated information
-
|
Aggregated volume
|
-
|
Price
|
|
N/A
|
e)
|
Date of the transaction
|
2024-03-04
|
f)
|
Place of the transaction
|
Outside a trading venue
|
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery and global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has approximately 5,000 personnel across
all its companies, at the center of which is a team of about 1,800
in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the
first of which is also marketed in the U.S. For more information,
please visit: www.hutch-med.com or follow us on
LinkedIn.
CONTACTS
Investor Enquiries
|
+852 2121 8200 /
+1 973 306 4490 / ir@hutch-med.com
|
|
|
Media Enquiries
|
|
Ben Atwell / Alex Shaw, FTI
Consulting
|
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
HUTCHMED@fticonsulting.com
|
Zhou Yi, Brunswick
|
+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
|
|
|
Nominated Advisor
|
|
Atholl Tweedie / Freddy
Crossley / Daphne Zhang,
Panmure Gordon
|
+44 (20) 7886 2500
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHJIMFTMTJMBAI
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
Von Sep 2023 bis Sep 2024